---
schema_version: "secwatch.filing_event.v1"
accession: "0001570562-24-000114"
form_type: "8-K"
ticker: "EOLS"
cik: "0001570562"
company_name: "Evolus, Inc."
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:22:39.016438+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Evolus Q2 revenue $66.9M (+36% YoY); raises FY2024 guidance to $260-270M; first positive non-GAAP operating income

## Summary
- Total net revenue of $66.9M for Q2 2024, up 36% YoY from $49.3M.
- GAAP operating loss improved to $7.7M; first positive non-GAAP operating income of $1.1M.
- Raised full-year 2024 net revenue guidance to $260M-$270M (top end 34% YoY growth).
- PMA submitted to FDA for Evolysse Lift and Smooth fillers; approval and launch expected H2 2025.
- Added 770 new customer accounts; total ~14,000 since launch; reorder rate ~70%.

## SEC filing metadata
- accession: 0001570562-24-000114
- form_type: 8-K
- ticker: EOLS
- cik: 0001570562
- company_name: Evolus, Inc.
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1570562/000157056224000114/0001570562-24-000114-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1570562/000157056224000114/eols-20240731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001570562-24-000114
- JSON: https://secwatch.observer/filing/0001570562-24-000114.json
- Plain text: https://secwatch.observer/filing/0001570562-24-000114.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.